Lasofoxifene
| CAS No. | 180916-16-9 |
|---|---|
| MDL No. | N/A |
| MF | C28H31NO2 |
| MW | 413.50 |
| InChI Key | GXESHMAMLJKROZ-IAPPQJPRSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Lasofoxifene is a 5,6,7,8-tetrahydronaphthalen-2-ol with the hydrogens at positions 5 and 6 replaced by 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl and phenyl groups (the 5R,6S-stereoisomer), respectively. It is a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis in post-menopausal women. It functions as an antineoplastic agent, cardioprotective agent, estrogen receptor agonist, antagonist, and bone density conservation agent. It belongs to the classes of tetralins, aromatic ethers, naphthols, and N-alkylpyrrolidines.
| CAS No. | 180916-16-9 |
|---|---|
| Product Name | Lasofoxifene |
Biological Targets
ESR2·ESR1
Associated Conditions
menopause·breast cancer·postmenopausal osteoporosis·osteoporosis·angiosarcoma·
* The information provided here is compiled from public sources and is for reference only.
